SR-1664
SR-1664 is a synthetic compound that has been studied for its potential effects on metabolic disorders, particularly in the context of type 2 diabetes mellitus. It is classified as a selective modulator of the peroxisome proliferator-activated receptor gamma (PPARγ), which is a nuclear receptor involved in the regulation of glucose and lipid metabolism.
Mechanism of Action[edit | edit source]
SR-1664 functions as a selective PPARγ modulator (SPPARM). Unlike full agonists of PPARγ, such as thiazolidinediones, SR-1664 does not activate the receptor to the same extent, which may reduce the risk of side effects associated with full activation. The compound binds to PPARγ and induces a conformational change that selectively modulates the receptor's activity, potentially improving insulin sensitivity without causing significant weight gain or fluid retention.
Research and Development[edit | edit source]
SR-1664 was developed as part of efforts to find safer alternatives to traditional PPARγ agonists. Preclinical studies have shown that SR-1664 can improve insulin sensitivity in animal models of diabetes without the adverse effects typically associated with PPARγ activation. However, as of the latest updates, SR-1664 has not yet advanced to clinical trials in humans.
Potential Benefits[edit | edit source]
The selective modulation of PPARγ by SR-1664 offers several potential benefits:
- Improved Insulin Sensitivity: By enhancing the body's response to insulin, SR-1664 may help in controlling blood glucose levels in diabetic patients.
- Reduced Side Effects: The selective action of SR-1664 aims to minimize side effects such as weight gain and edema, which are common with full PPARγ agonists.
Challenges and Considerations[edit | edit source]
While SR-1664 shows promise, there are several challenges that need to be addressed:
- Efficacy in Humans: The efficacy and safety of SR-1664 in humans remain to be established through clinical trials.
- Long-term Effects: The long-term impact of selective PPARγ modulation is not fully understood and requires further investigation.
Also see[edit | edit source]
- Type 2 diabetes mellitus
- Peroxisome proliferator-activated receptor
- Thiazolidinediones
- Insulin resistance
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
